Paola Secchiero

发表

Potential pathogenetic implications of cyclooxygenase-2 overexpression in B chronic lymphoid leukemia cells.

Stefano A Pileri, Claudio Agostinelli, S. Pileri, 2005, American Journal of Pathology.

The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies.

P. Secchiero, A. Gonelli, G. Zauli, 2008, Current pharmaceutical design.

Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism.

P. Secchiero, F. Corallini, G. Zauli, 2009, Blood.

Recent advances in the therapeutic perspectives of Nutlin-3.

P. Secchiero, G. Zauli, Paola Secchiero, 2011, Current pharmaceutical design.

COVID-19 and Individual Genetic Susceptibility/Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-Chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X-Chromosome in Males?

P. Secchiero, G. Zauli, B. Bramanti, 2020, International journal of molecular sciences.

miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation.

Hansjuerg Alder, Cristian Taccioli, Mario Acunzo, 2009, Cancer cell.

Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism.

P. Secchiero, F. Corallini, G. Zauli, 2009, Blood.

MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC

Alessandro Laganà, Carlo M. Croce, Justin Middleton, 2015, Proceedings of the National Academy of Sciences.

Antiangiogenic Activity of the MDM2 Antagonist Nutlin-3

A. Albini, P. Secchiero, F. Corallini, 2007, Circulation research.

microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival.

George A Calin, Kevin R Coombes, Muller Fabbri, 2010, Blood.